Gossamer Bio, Inc.(GOSS)Stock Analysis

GOSS Stock Analysis & AI Quality Score

AI stock analysis and institutional research for Gossamer Bio, Inc. (GOSS), a Healthcare sector company. 13F Pro's AI-powered ranking engine scores GOSS at 27.1/100 on a 32-signal composite quality model, placing it at rank #2,479 of 2,879 stocks — the bottom half of the AI-ranked universe. GOSS scores in the top quartile across revenue growth (95.7). Areas of concern include balance sheet strength (0.7) and profitability (4.3), which score below median versus the broader universe. Shareholder dilution risk is elevated at 8.7/100, reflecting ongoing share issuance or stock-based compensation. Based on the latest XBRL financial filings (Q1 2026), Gossamer Bio, Inc. reports quarterly revenue of $17.0M, net income of $-46.7M, free cash flow of $-38.7M. Top institutional holders of GOSS by reported 13-F value include Context Capital Management,, D. E. Shaw & Co.,, DeepCurrents Investment Group, based on the most recent SEC filings. GOSS trades on the Nasdaq exchange and files with the SEC under CIK 1728117. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate GOSS daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Gossamer Bio, Inc. directly from SEC EDGAR. Gossamer Bio, Inc.'s 13F Pro composite quality score has ranged between 11 and 27 since 2025, currently 27.1 — an improving long-term trajectory across 12 quarterly and live scoring snapshots.